FinnCap restated their corporate rating on shares of Premaitha Health PLC (LON:NIPT) in a research note released on Friday morning. The firm currently has a GBX 20 ($0.26) price objective on the stock.

Separately, Panmure Gordon reiterated a buy rating and issued a GBX 24 ($0.31) target price on shares of Premaitha Health PLC in a research report on Monday, July 4th.

Premaitha Health PLC (LON:NIPT) traded down 1.060% during midday trading on Friday, hitting GBX 10.265. The stock had a trading volume of 821,784 shares. Premaitha Health PLC has a one year low of GBX 6.50 and a one year high of GBX 21.50. The firm’s market cap is GBX 23.42 million. The stock has a 50-day moving average price of GBX 10.45 and a 200 day moving average price of GBX 9.58.

Premaitha Health PLC Company Profile

Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques. The Company’s techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease.

Receive News & Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related companies with's FREE daily email newsletter.